INCLINE VILLAGE, Nev.
Jan. 30, 2013
/PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its board of directors has declared that the regular, quarterly dividends to be paid to its stockholders in 2013 will be
per share of common stock. The
dividends will each be paid on
of 2013 to all stockholders who own shares of PDL on
of 2013, the record dates for each of the dividend payments, respectively.
"We are pleased to announce that we will pay regular quarterly dividends for 2013 to our shareholders totaling
per share for the year," said
John P. McLaughlin
, president and chief executive officer of PDL BioPharma. "This will be the fifth consecutive year that PDL has paid either a special or regular dividend and the third consecutive year that it will pay a regular dividend."
Stockholders desiring to purchase shares with rights to the dividend must ensure that their trades are executed prior to the "ex-dividend" date and settle prior to the record date. NASDAQ will establish an ex-dividend date that is generally two business days prior to the record date. Investors should consult with their brokers or financial advisors regarding their specific situations.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new revenue generating assets and maximizing value for its shareholders. For more information, please visit
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.